|Videos|August 19, 2011

ASCO: Impact of 2 New Drugs for the Treatment of Metastatic Melanoma

Dr. Antoni Ribas, UCLA’s Jonsson Comprehensive Cancer Center and a presenter at this year’s annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.

Dr. Antoni Ribas, UCLA's Jonsson Comprehensive Cancer Center and a presenter at this year's annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

ASCO: Impact of 2 New Drugs for the Treatment of Metastatic Melanoma

Related Content

FDA Approves PGDx Elio Tissue Complete CDx for Advanced Melanoma

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma

TIL Cell Therapy in HIV Positive Patient With Metastatic Melanoma: Case Report

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

RP1's Long Road: A Timeline of RP1's Regulatory Journey in Advanced Melanoma

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Arizona

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

25th Annual International Congress on the Future of Breast Cancer® East

25th Annual International Congress on the Future of Breast Cancer® West

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Indiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Tennessee Oncology Practice Society

Kansas Society of Clinical Oncology

Satellite Symposia at the Annual Radiation Oncology Meeting

27th Annual International Lung Cancer Congress®

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Texas Society of Clinical Oncology

North Carolina Oncology Association

Louisiana Oncology Society

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Diagnosis and Management of TGCT

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Optimizing Multidisciplinary Care in TGCT

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Trending on CancerNetwork

What Are The Biggest Misconceptions About CAR T Cells in Multiple Myeloma?

Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status

FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma

Defining the Objectives of an Analysis of Tarlatamab in Brain Metastases

The Rationale for JAK Inhibition/PD-1 Blockade in Immune-Resistant RCC